COMMUNIQUÉS West-GlobeNewswire

AskBio Presents Baseline Characteristics from Phase 2 Heart Failure Gene Therapy Trial of Umiposgene Parvec (AB-1002) at European Society of Cardiology Congress
29/08/2026
Durham, N.C., Aug. 29, 2026 (GLOBE NEWSWIRE) -- Phase 2 GenePHIT trial successfully randomized and completed enrollment of one of the largest gene therapy trials conducted in heart failure to date, with more than 170 [...]
Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
29/08/2026
Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM New Analysis of MAPLE-HCM Finds Aficamten Outperformed Metoprolol Across Pre- [...]
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
29/08/2026
In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112) In the same patient population, TNX-103 produced a 47% [...]
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
29/08/2026
CEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader [...]
Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update
28/08/2026
- Continued execution of transformation strategy drives commercial, manufacturing and pipeline progress - PrePsia™ patent portfolio expands to nine granted U.S. and European patents - Company issues update on Nasdaq [...]
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
28/08/2026
SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery [...]
NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
28/08/2026
TORONTO and HAIFA, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biotechnology company developing exosome-based regenerative [...]
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28/08/2026
VANCOUVER, BC and BOSTON, MA, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and [...]
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
28/08/2026
Company announcement – No. 43 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, August [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 juillet 2026
28/08/2026
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]
EmblemHealth Helps New York City Students Start the School Year Strong
28/08/2026
EmblemHealth and local partners distributed thousands of backpacks, school supplies, and nutritious food to families across the five boroughs. PHOTO (Left to right): Council Member Sandra Ung, EmblemHealth VP Enterprise [...]
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
28/08/2026
-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026- -Phase 1a clinical data for CTX310 ® continued to demonstrate robust, dose-dependent reductions in circulating [...]
NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger
28/08/2026
DENVER, Aug. 28, 2026 (GLOBE NEWSWIRE) -- For NeOnc Technologies Holdings (NASDAQ: NTHI) , the most important part of the NEO100 story may no longer be whether the company can produce a meaningful signal in recurrent [...]
Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions
28/08/2026
$8 million senior secured ATW convertible note satisfied , together with all accrued interest, twelve months ahead of its August 2027 maturity and eliminating any further dilution Simplified capital structure , with no [...]
Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center
28/08/2026
Physician-Aligned Collaboration to Support a Regional Sleep & Airway Medicine Center in Palm Beach County LITTLETON, Colo., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") ( [...]
DirectMeds Announces Expanded Access to Doctor-Guided GLP-1 Weight Management Programs Starting at $249 Per Month
28/08/2026
New York, NY, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Telehealth platform expands access to physician-guided GLP-1 treatment with transparent pricing, nationwide virtual care, and ongoing clinical support. DirectMeds today [...]
INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
28/08/2026
Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a [...]
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
28/08/2026
Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents DOYLESTOWN, Pa., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a [...]
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients
28/08/2026
Data Supports Approximately 30% Relative Risk Reduction Among Highly Adherent Patients and Provides Evidence Consistent with a Potential Legacy Effect in Secondary Prevention Patients After Treatment Discontinuation [...]

Pages